Understand diabetic retinopathy treatment options: A U.S. guide to care, risks, and costs

Key facts

• Anti-VEGF eye injections are reported at roughly $50 to more than $2,600 per dose in the United States in 2026.1
• Laser treatment estimates can start around $300 per session, although facility and professional charges may vary.2
• Diabetic retinopathy care may involve monitoring, injections, laser treatment, corticosteroids, vitrectomy, or combinations of these approaches.3
• Wills Eye Hospital is an example of a specialist center associated with vitreoretinal disease and surgery expertise.3

Understanding diabetic retinopathy treatment options requires separating early retinal changes from diabetic macular edema, proliferative disease, bleeding, and retinal detachment. A qualified ophthalmologist, particularly a retina specialist, determines whether observation, medication, laser treatment, or surgery is appropriate after a dilated examination and retinal imaging. The information below describes U.S. care in general and is not a diagnosis or individualized treatment plan.

How diabetic retinopathy is assessed

Diabetic retinopathy is damage to the retina’s small blood vessels associated with diabetes. Nonproliferative disease involves vessel leakage, bleeding, or reduced blood flow, while proliferative disease can produce fragile new vessels that bleed or pull on the retina. Diabetic macular edema, or DME, occurs when fluid affects the macula, the area responsible for detailed central vision. These conditions can occur together and may require different approaches.

Assessment commonly includes a dilated retinal examination, optical coherence tomography, and sometimes fundus photography or fluorescein angiography. Merck Manual describes these tests as useful for identifying edema, abnormal vessel growth, vitreous hemorrhage, and tractional retinal detachment.3 Disease severity, the location of swelling, kidney function, blood pressure, diabetes control, and findings in each eye can affect follow-up intervals and treatment selection.

Monitoring and injectable medicines

Observation may be appropriate when retinopathy is mild, inactive, or not yet causing a treatment indication. Monitoring is not the same as ignoring the condition: appointments may include repeat imaging and examinations to identify progression. More advanced disease or centrally involved DME may lead a retina specialist to recommend an intravitreal injection, in which medicine is placed into the vitreous cavity under sterile conditions.

Anti-VEGF medicines reduce signals that promote abnormal blood-vessel growth and leakage. Commonly discussed agents include aflibercept, ranibizumab, and bevacizumab, while newer therapies may also be considered under specialist guidance.3 Injections often require repeated visits and monitoring. Risks include eye infection, inflammation, bleeding, temporary pressure changes, and retinal complications. The choice of medicine depends on clinical findings, regulatory status, prior response, availability, and coverage rules.

Laser and corticosteroid treatments

Laser photocoagulation uses focused light to treat selected retinal areas. Focal or grid laser may target leakage associated with some forms of macular edema, while panretinal photocoagulation treats broader peripheral retinal areas when abnormal new vessels develop. Laser does not involve placing medicine inside the eye, but it can cause temporary discomfort, inflammation, blind spots, or changes in peripheral or night vision depending on the area treated.

Corticosteroids may be delivered by injection or a sustained-release implant in selected cases of DME or persistent inflammation. They can be useful when anti-VEGF treatment is unsuitable or insufficient, but they require pressure and lens monitoring. Possible risks include increased eye pressure, glaucoma, cataract development, inflammation, and infection. Published clinical summaries identify laser, anti-VEGF medicines, corticosteroids, and surgery as established components of diabetic retinal care.3

Surgery for bleeding or retinal complications

Vitrectomy removes some or all of the vitreous gel from inside the eye. A vitreoretinal surgeon may consider it for persistent vitreous bleeding, tractional retinal detachment, or other complications that cannot be managed adequately with injections or laser. The surgeon may use saline, a gas bubble, or silicone oil during the procedure, depending on the retinal problem. Surgery may take place in a hospital or ambulatory surgical setting.

Recovery can involve blurred vision, restrictions on lifting or positioning, and several postoperative examinations. Risks include infection, bleeding, increased eye pressure, cataract formation, recurrent retinal problems, and complications related to a gas bubble or silicone oil. Vitrectomy is therefore generally reserved for particular complications rather than routine early retinopathy. Specialist services include hospital-based vitreoretinal departments and dedicated eye centers, with Wills Eye Hospital cited as an example of a center associated with vitreoretinal disease and surgery expertise.3

Where specialist care is provided

Diabetic retinopathy treatment is typically provided through hospital eye departments, academic ophthalmology centers, ambulatory eye-surgery facilities, and private retina clinics. A general ophthalmologist may identify disease and arrange referral, while a retina specialist interprets imaging and selects among injections, laser, corticosteroids, and surgery. The appropriate setting depends on the procedure, anesthesia needs, medical complexity, and whether urgent bleeding or retinal traction is present.

Waiting times vary by region, referral pathway, appointment capacity, and urgency. Stable monitoring cases may be scheduled later than suspected proliferative disease, sudden vitreous bleeding, or retinal detachment. Referral records should include recent eye examinations, imaging, diabetes history, medicines, and previous retinal procedures. A qualified ophthalmologist should explain whether treatment is needed promptly, what follow-up schedule is expected, and whether another specialist opinion would clarify the choices.

Typical U.S. costs and coverage considerations

Costs vary by medicine, facility, geography, imaging, clinician fees, anesthesia, and the number of visits. A 2026 cost summary reports anti-VEGF injections ranging from roughly $50 for off-label bevacizumab to more than $2,600 for newer branded medicines.1 Another 2026 guide describes laser treatment as starting around $300 per session and notes that published prices may represent only part of the total bill.2

Public programs and private health coverage may pay for medically necessary examinations, injections, laser procedures, or surgery, subject to eligibility, authorization, deductibles, copayments, and provider rules. Coverage does not necessarily eliminate out-of-pocket costs. Before treatment, the ophthalmology office can provide an itemized estimate covering the examination, imaging, medicine, facility, anesthesia, and follow-up. Questions should also address the likely number of visits, alternatives, side effects, warning symptoms, and the consequences of delaying care.

Sources

1. Diabetic Retinopathy Treatment Cost: Injections, Surgery & Insurance - LegalClarity: https://legalclarity.org/diabetic-retinopathy-treatment-cost-injections-surgery-insurance/
2. Diabetic Retinopathy Treatment Cost 2026: $300–$4,000 per Eye per Session — VisionCostGuide: https://visioncostguide.com/guides/diabetic-retinopathy-treatment-cost/
3. Diabetic Retinopathy - Ophthalmology - Merck Manual Professional Edition: https://www.merckmanuals.com/professional/eye-disorders/retinal-disorders/diabetic-retinopathy